Precision BioSciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
DTIL Nasdaq 8731 https://precisionbiosciences.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Precision BioSciences Inc

Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last? - Apr 17th, 2024 11:36 am
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics - Apr 16th, 2024 8:15 pm
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy? - Apr 11th, 2024 1:55 pm
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know - Apr 2nd, 2024 1:55 pm
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock? - Apr 2nd, 2024 10:48 am
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates - Mar 27th, 2024 12:10 pm
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update - Mar 27th, 2024 10:45 am
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024 - Mar 20th, 2024 8:30 pm
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy - Mar 19th, 2024 11:00 am
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency - Mar 6th, 2024 1:45 pm
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants - Mar 1st, 2024 11:30 am
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants - Feb 29th, 2024 9:01 pm
Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength? - Feb 27th, 2024 9:25 am
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences - Feb 20th, 2024 12:00 pm
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness - Feb 14th, 2024 12:00 pm
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations - Feb 13th, 2024 12:00 pm
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases - Feb 12th, 2024 12:00 pm
Precision BioSciences to Effect a Reverse Stock Split - Feb 9th, 2024 12:00 pm
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases - Jan 9th, 2024 12:00 pm
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases - Jan 9th, 2024 12:00 pm